Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| GLUE | CLUSTER | neutral | 2/10 | A cluster of insider sales and option exercises at Monte Rosa Therapeutics over the past week saw Chief Medical Officer | Jun 26, 2026 |
| DCOY | EFFECT | neutral | 5/10 | The SEC declared Decoy Therapeutics Inc.'s S-1 registration statement effective on June 24, 2026, enabling the company t | Jun 25, 2026 |
| RAJAF | 6-K | neutral | 3/10 | Cordyceps Sunshine Biotech entered into a Cooperation and Development Agreement with Pet Sunshine Biological Research fo | Jun 25, 2026 |
| HCM | 6-K | bullish | 7/10 | HUTCHMED reported pivotal Phase II data for fanregratinib in FGFR2-fusion intrahepatic cholangiocarcinoma, showing a 42. | Jun 25, 2026 |
| MLTX | 8-K | bearish | 6/10 | MoonLake Immunotherapeutics priced a $200M public offering of 9M shares at $20.00 and 1M pre-funded warrants at $19.9999 | Jun 25, 2026 |
| MSLE | 6-K | neutral | 3/10 | Satellos announced a poster and showcase presentation at ICNMD 2026 covering six-month follow-up data from its Phase 1b | Jun 25, 2026 |
| TLSA | 6-K | neutral | 4/10 | Tiziana Life Sciences announced that the last patient in its Phase 2a INFORM-MS trial of intranasal foralumab for non-ac | Jun 25, 2026 |
| RDHL | 6-K | neutral | 3/10 | RedHill Biopharma filed a 6-K containing the notice and proxy statement for its annual general meeting on July 28, 2026. | Jun 25, 2026 |
| QURE | 144 | bearish | 5/10 | CEO Matthew Kapusta filed a Form 144 to sell 28,716 ordinary shares (~$1.44M) under a 10b5-1 plan adopted in October 202 | Jun 25, 2026 |
| QTTB | S-3 | neutral | 3/10 | Q32 Bio filed an S-3 shelf registration to issue an unlimited amount of senior or subordinated debt securities. This is | Jun 25, 2026 |
| DFTX | 144 | neutral | 3/10 | Mark Sullivan, an officer of Definium Therapeutics, filed a Form 144 notice of intent to sell 13,008 shares of common st | Jun 25, 2026 |
| PRFX | 6-K | neutral | 4/10 | PRF Technologies reported expanded preclinical data for PRF-110, showing comparable analgesic efficacy to approved bench | Jun 25, 2026 |
| CELZ | S-1 | neutral | 5/10 | Creative Medical Technology Holdings (CELZ) filed an S-1 registration statement for a best-efforts public offering of up | Jun 25, 2026 |
| TSHA | 424B5 | bearish | 6/10 | Taysha Gene Therapies is raising approximately $187.4 million ($215.6 million if underwriters' option is exercised) thro | Jun 25, 2026 |
| ADPT | 144 | neutral | 2/10 | Director Michelle Griffin filed a Form 144 on June 25, 2026, indicating intent to sell 52,084 shares of Adaptive Biotech | Jun 25, 2026 |
| PHVS | 144 | neutral | 2/10 | Director/10%-owner Lu Peng filed a Form 144 notice to sell 15,000 common shares valued at approximately $499,350. The sa | Jun 25, 2026 |
| TSHA | 8-K | mixed | 5/10 | Taysha Gene Therapies priced a $200M underwritten public offering of 32,500,001 common shares at $6.00/share and 833,333 | Jun 25, 2026 |
| CLLS | 6-K | neutral | 4/10 | Cellectis S.A. held its Combined General Meeting of Shareholders on June 25, 2026, and all 30 proposed resolutions were | Jun 25, 2026 |
| ATAI | 144 | neutral | 3/10 | Kevin Craig, an officer of AtaiBeckley, filed a Form 144 on June 25, 2026, to sell 85,158 shares of common stock via Mor | Jun 25, 2026 |
| VTRS | 144 | neutral | 3/10 | Viatris officer Paul Campbell filed a Form 144 notice of intent to sell 50,076 shares of common stock, with an approxima | Jun 25, 2026 |
| CTKB | 8-K | neutral | 2/10 | Chief Legal Officer and Corporate Secretary Valerie Barnett is departing Cytek Biosciences effective June 29, 2026. The | Jun 25, 2026 |
| AYTU | 8-K | neutral | 2/10 | Aytu BioPharma and Lannett Company mutually terminated their exclusive license agreement for Metadate CD, effective June | Jun 25, 2026 |
| CLLS | 6-K | neutral | 2/10 | Cellectis reported results from its June 25, 2026 shareholders meeting, where 29 of 30 resolutions were adopted and only | Jun 25, 2026 |
| AAWH | PREM14A | neutral | 3/10 | Ascend Wellness Holdings filed a preliminary proxy statement to convene a special meeting on August 28, 2026, seeking st | Jun 25, 2026 |
| GRML | 8-K | bearish | 6/10 | Greenland Mines Ltd. completed a private placement on June 18, 2026, issuing 15,000,000 shares of common stock at $0.25 | Jun 25, 2026 |
| TECH | DEFA14A | bullish | 8/10 | Bio-Techne has entered into a definitive agreement to be acquired by Merck KGaA for $73.00 per share in cash. The deal i | Jun 25, 2026 |
| LGND | 8-K | mixed | 6/10 | Ligand Pharmaceuticals issued $700M of 0.00% Convertible Senior Notes due 2031, with an initial conversion price of appr | Jun 25, 2026 |
| HRTX | 8-K | bearish | 7/10 | Heron Therapeutics received a Nasdaq deficiency notice on June 25, 2026, for failing to maintain a minimum $1.00 closing | Jun 25, 2026 |
| SPRO | 8-K | neutral | 3/10 | Spero Therapeutics filed an 8-K reporting shareholder approval to double authorized common shares from 120M to 240M and | Jun 25, 2026 |
| ADXN | 6-K | bearish | 7/10 | Addex Therapeutics filed its Q1 2026 6-K, reporting a net loss of CHF 1.7M, with cash of CHF 935k sufficient only throug | Jun 25, 2026 |